News | Peripheral Artery Disease (PAD) | September 13, 2017

PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages

Subset analysis from DETOUR I study presented during VIVA 17 late-breaking clinical trial session

PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages

September 13, 2017 — A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), Sept. 11-14 in Las Vegas. DETOUR I trial results were presented by Sean Lyden, M.D., chairman of the department of Vascular Surgery at Cleveland Clinic.

In complex peripheral artery disease (PAD), arteries in the leg can become blocked by long segments of plaque that restrict blood flow to the lower leg and foot. This can lead to pain, loss of mobility and amputation. Extremely long blockages, such as those greater than 20 cm, are quite challenging to treat. Historically, physicians have treated these blockages with open bypass surgery, which has the benefit of durability; however, it is associated with an increased risk of complications, longer hospital stays and prolonged rehabilitation. Minimally invasive approaches to PAD, including angioplasty and stenting, work very well on shorter blockages; however, they have not been as effective on longer ones.

“Patients with long segment femoropopliteal blockages are in need of advanced therapeutic alternatives to existing treatments. While endovascular revascularization is effective in shorter lesions, its durability in longer segment blockages has not matched that of open surgery. Fully percutaneous bypass is designed to combine the durability advantages of surgical bypass with the minimally invasive advantages of a percutaneous procedure,” said Lyden. “The outcomes we are seeing in the DETOUR I trial indicate that a fully percutaneous bypass procedure has potential to fill this gap in treatment options.”

The analysis of a subset of the DETOUR I study presented at VIVA 17 is one of the largest prospective series ever to evaluate the percutaneous treatment of femoropopliteal blockages with lengths of 25-45 cm (mean of 33.8 cm). The six-month outcomes from 50 patients demonstrated the Detour System’s ability to successfully treat these long blockages without significant impact on venous health and low rates of major adverse events (MAEs). The results included:

  • Primary safety endpoint: 2 percent MAEs – defined as death, target vessel revascularization (TVR) or amputation at 30 days. There were no deaths or amputations and one TVR.1;
  • Primary patency of 88.9 percent at six months with optimal placement, overall primary patency of 76.9 percent;
  • Successful delivery of devices to the identified area and removal of the delivery system in 100 percent of lesions (53/53);
  • Improvement in Rutherford Class of at least 2 grades in 92 percent of patients (45/49)2;
  • Significant improvement in ankle brachial index from 0.64 ± 0.17 to 0.92 ± 0.14 (p<0.0001); and
  • No impact on venous function and no device-related deep vein thrombosis in treated vessels .

Percutaneous femoropopliteal bypass (the Detour procedure) is a newly developed procedure that utilizes PQ Bypass’ proprietary Detour System technologies — the Torus Stent Graft, Detour Crossing Device and Detour Snare — to provide fully percutaneous bypass of long-segment blockages in the femoropopliteal artery. The Detour procedure creates a pathway around a lesion by placing stent grafts that cross from the superficial femoral artery (SFA) into the femoral vein and back into the artery. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

In March 2017, PQ Bypass received CE  Mark approval for all three devices that are included in the Detour System.

For more information: www.pqbypass.com

 

1. One patient underwent TVR graft disassociation resulting in acute limb ischemia prior to discharge, treated successfully with an additional DETOUR Stent Graft

2. Excludes a subject who died from ischemic stroke prior to 6-month follow-up

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init